Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis-stimulating agents: new insights

被引：75

作者：

Macdougall, Iain C. ^{[1
]}

Roger, Simon D. ^{[2
]}

de Francisco, Angel ^{[3
]}

Goldsmith, David J. A. ^{[4
]}

Schellekens, Huub ^{[5
]}

Ebbers, Hans ^{[5
]}

Jelkmann, Wolfgang ^{[6
]}

London, Gerard ^{[7
]}

Casadevall, Nicole ^{[8
]}

Hoerl, Walter H. ^{[9
]}

Kemeny, David M. ^{[10
]}

Pollock, Carol ^{[11
]}

机构：

[1] Kings Coll Hosp London, Renal Unit, London SE5 9RS, England

[2] Gosford Hosp, Gosford, NSW, Australia

[3] Hosp Univ Valdecilla, Santander, Spain

[4] Guys Hosp, London SE1 9RT, England

[5] Univ Utrecht, Utrecht, Netherlands

[6] Univ Lubeck, Lubeck, Germany

[7] Ctr Hosp Manhes, Fleury Merogis, France

[8] Hop St Antoine, F-75571 Paris, France

[9] Med Univ Vienna, Vienna, Austria

[10] Natl Univ Singapore, Singapore 117548, Singapore

[11] Univ Sydney, Sydney, NSW 2006, Australia

来源：

KIDNEY INTERNATIONAL | 2012年 / 81卷 / 08期

关键词：

anemia; chronic kidney disease; clinical nephrology; pure red cell aplasia; RECOMBINANT-HUMAN-ERYTHROPOIETIN; ANTIERYTHROPOIETIN ANTIBODIES; NEUTRALIZING ANTIBODIES; INTERFERON-BETA; EPOETIN-ALPHA; IMMUNOGENICITY; BIOPHARMACEUTICALS; ASSOCIATION; PROTEINS; EFFICACY;

D O I：

10.1038/ki.2011.500

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Antibody-mediated pure red cell aplasia is a very rare but devastating condition affecting patients receiving treatment with erythropoiesis-stimulating agents. New cases continue to emerge, generally in clusters, consistent with an 'environmental' trigger to its pathogenesis. Defining the causes of antibody-mediated pure red cell aplasia is clearly of importance for patients with chronic kidney disease, but any developments in this area may also have relevance to other disease areas as therapeutic delivery of endogenous proteins rapidly increases. This review focuses on the current knowledge regarding the etiology of antibody-mediated pure red cell aplasia and the current approach to therapy. Kidney International (2012) 81, 727-732; doi:10.1038/ki.2011.500; published online 15 February 2012

引用

页码：727 / 732

页数：6

共 47 条

[1] Successful reintroduction of a different erythropoiesis-stimulating agent after pure red cell aplasia: relapse after successful therapy with prednisone [J].

Andrade, J ;

Taylor, PA ;

Love, JM ;

Levin, A .

NEPHROLOGY DIALYSIS TRANSPLANTATION, 2005, 20 (11) :2548-2551

[2]

[Anonymous], 2010, GUID NONCL CLIN DEV

[3] Precipitation of a Monoclonal Antibody by Soluble Tungsten [J].

Bee, Jared S. ;

Nelson, Stephanie A. ;

Freund, Erwin ;

Carpenter, John F. ;

Randolph, Theodore W. .

JOURNAL OF PHARMACEUTICAL SCIENCES, 2009, 98 (09) :3290-3301

[4]

Bennett CL, 2004, NEW ENGL J MED, V351, P1385

[5] Quality of Original and Biosimilar Epoetin Products [J].

Brinks, Vera ;

Hawe, Andrea ;

Basmeleh, Abdul H. H. ;

Joachin-Rodriguez, Liliana ;

Haselberg, Rob ;

Somsen, Govert W. ;

Jiskoot, Wim ;

Schellekens, Huub .

PHARMACEUTICAL RESEARCH, 2011, 28 (02) :386-393

[6]

Brockmeyer C, 2009, EJHP PRACT, V15, P34

[7] Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. [J].

Casadevall, N ;

Nataf, J ;

Viron, B ;

Kolta, A ;

Kiladjian, J ;

Martin-Dupont, P ;

Michaud, P ;

Papo, T ;

Ugo, V ;

Teyssandier, I ;

Varet, B ;

Mayeux, P .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (07) :469-475

[8] Brief report: Autoantibodies against erythropoietin in a patient with pure red-cell aplasia [J].

Casadevall, N ;

Dupuy, E ;

MolhoSabatier, P ;

Tobelem, G ;

Varet, B ;

Mayeux, P .

NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (10) :630-633

[9] Biosimilars need comparative clinical data [J].

Casadevall, Nicole ;

Thorpe, Robin ;

Schellekens, Huub .

KIDNEY INTERNATIONAL, 2011, 80 (05) :553-553

[10]

Chailimpamontree W, 2011, 48 ERA EDTA C PRAG C

← 1 2 3 4 5 →